MCID: GLL018
MIFTS: 67

Gallbladder Cancer

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gallbladder Cancer

MalaCards integrated aliases for Gallbladder Cancer:

Name: Gallbladder Cancer 12 49 36 51 40 14
Gallbladder Carcinoma 12 51 14 69
Malignant Neoplasm of Gallbladder 12 69
Gallbladder Neoplasm 12 69
Malignant Neoplasm of Gallbladder Localized 69
Localized Malignant Gallbladder Neoplasm 12
Malignant Tumor of the Gallbladder 12
Malignant Tumour of Gallbladder 12
Cancer of the Gallbladder 12
Tumor of the Gallbladder 12
Carcinoma of Gallbladder 12
Carcinoma Gallbladder 12
Gallbladder Neoplasms 41
Gallbladder Ca 12

Classifications:



Summaries for Gallbladder Cancer

MedlinePlus : 40 Your gallbladder is a pear-shaped organ under your liver. It stores bile, a fluid made by your liver to digest fat. As your stomach and intestines digest food, your gallbladder releases bile through a tube called the common bile duct. The duct connects your gallbladder and liver to your small intestine. Cancer of the gallbladder is rare. It is more common in women and Native Americans. Symptoms include Jaundice (yellowing of the skin and whites of the eyes) Pain above the stomach Fever Nausea and vomiting Bloating Lumps in the abdomen It is hard to diagnose gallbladder cancer in its early stages. Sometimes doctors find it when they remove the gallbladder for another reason. But people with gallstones rarely have gallbladder cancer. Because it is often found late, it can be hard to treat gallbladder cancer. Treatment options include surgery, chemotherapy, radiation, or a combination. NIH: National Cancer Institute

MalaCards based summary : Gallbladder Cancer, also known as gallbladder carcinoma, is related to biliary tract neoplasm and cholangiocarcinoma, and has symptoms including gastrointestinal gas, nausea and vomiting and icterus. An important gene associated with Gallbladder Cancer is MLH1 (MutL Homolog 1), and among its related pathways/superpathways are ERK Signaling and Cytokine Signaling in Immune system. The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include the gallbladder, liver and lymph node, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A biliary tract cancer that is located in the gallbladder.

Wikipedia : 72 Gallbladder cancer is a relatively uncommon cancer. It has peculiar geographical distribution being... more...

Related Diseases for Gallbladder Cancer

Diseases related to Gallbladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 272)
# Related Disease Score Top Affiliating Genes
1 biliary tract neoplasm 31.3 CDKN2A KRAS MUC1 MUC2 TP53
2 cholangiocarcinoma 30.8 AFP CDH1 CEACAM5 ERBB2 KRAS MUC1
3 cholecystitis 30.0 ABCB4 CDH1 CDKN2A MUC1 MUC2 TP53
4 adenoma 28.9 KRAS MGMT MLH1 MUC2 PTGS2 TP53
5 mucinous adenocarcinoma 28.8 CDKN2A EGFR KRAS MLH1 MUC1 MUC2
6 intrahepatic cholangiocarcinoma 28.6 AFP CDH1 EGFR KRAS MUC1 MUC2
7 adenocarcinoma 28.3 AKT1 CDH1 CDKN2A EGFR ERBB2 KRAS
8 hepatocellular carcinoma 28.2 AFP AKT1 CDH1 CDKN2A CEACAM5 EGFR
9 bladder cancer 27.8 CDH1 CDKN2A EGFR ERBB2 KRAS MMP2
10 lung cancer 27.2 AKT1 CDH1 CDKN2A CEACAM5 EGFR ERBB2
11 adenosquamous gallbladder carcinoma 12.2
12 squamous cell carcinoma of gallbladder and extrahepatic biliary tract 12.0
13 gallbladder small cell carcinoma 11.2
14 gallbladder papillary carcinoma 10.9
15 brain stem astrocytic neoplasm 10.6 CDKN2A TP53
16 mucoepidermoid esophageal carcinoma 10.6 CEACAM5 TP53
17 sigmoid neoplasm 10.6 CEACAM5 KRAS
18 nasal cavity adenocarcinoma 10.6 CDKN2A KRAS TP53
19 breast papillomatosis 10.6 CDKN2A ERBB2
20 brain ependymoma 10.6 EGFR TP53
21 breast mucoepidermoid carcinoma 10.5 CEACAM5 MUC1
22 intracranial chondrosarcoma 10.5 CEACAM5 TP53
23 breast intraductal proliferative lesion 10.5 EGFR ERBB2
24 esophageal adenosquamous carcinoma 10.5 CDH1 CEACAM5
25 squamous cell carcinoma of the larynx 10.5 CDKN2A EGFR TP53
26 oral leukoplakia 10.5 CDKN2A ERBB2 TP53
27 nasal cavity squamous cell carcinoma 10.5 CDKN2A MMP2 TIMP2
28 microcystic meningioma 10.5 CDH1 MMP2 TIMP2
29 ovary adenocarcinoma 10.5 CEACAM5 KRAS TP53
30 gallbladder squamous cell carcinoma 10.5 CEACAM5 ERBB2
31 cerebral convexity meningioma 10.5 CDH1 TP53
32 nodular malignant melanoma 10.5 CDKN2A MMP2 TIMP2
33 breast cystic hypersecretory carcinoma 10.5 CDH1 ERBB2
34 apocrine adenoma 10.5 CEACAM5 KRAS MUC1
35 pulmonary blastoma 10.5 EGFR KRAS TP53
36 balanitis xerotica obliterans 10.5 CDKN2A PTGS2 TP53
37 mixed cell type cancer 10.5 ERBB2 KRAS TP53
38 oropharynx cancer 10.5 CDKN2A EGFR TP53
39 familial colorectal cancer 10.5 CDH1 MLH1 TP53
40 aggressive digital papillary adenocarcinoma 10.5 CEACAM5 KRAS MUC1
41 squamous cell carcinoma of the oropharynx 10.5 CDKN2A TP53
42 bladder squamous cell carcinoma 10.5 CDKN2A PTGS2 TP53
43 vulval paget's disease 10.5 CDKN2A CEACAM5 ERBB2
44 basaloid squamous cell carcinoma 10.5 CDKN2A EGFR TP53
45 vulva adenocarcinoma 10.5 CDKN2A CEACAM5 ERBB2
46 vulva cancer 10.5 CDKN2A EGFR TP53
47 malignant peritoneal mesothelioma 10.5 CDKN2A EGFR MUC1
48 megaesophagus 10.5 CDKN2A FHIT TP53
49 fallopian tube endometrioid adenocarcinoma 10.5 CDKN2A ERBB2
50 cervix uteri carcinoma in situ 10.5 CDKN2A FHIT TP53

Comorbidity relations with Gallbladder Cancer via Phenotypic Disease Network (PDN):


Cholangitis Cholestasis
Deficiency Anemia

Graphical network of the top 20 diseases related to Gallbladder Cancer:



Diseases related to Gallbladder Cancer

Symptoms & Phenotypes for Gallbladder Cancer

UMLS symptoms related to Gallbladder Cancer:


gastrointestinal gas, nausea and vomiting, icterus, heartburn, dyspepsia, diarrhea, constipation, abdominal pain

GenomeRNAi Phenotypes related to Gallbladder Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.58 EGFR KRAS
2 Decreased viability GR00106-A-0 9.58 KRAS
3 Decreased viability GR00221-A-1 9.58 AKT1 CDH1 CDKN2A EGFR KRAS
4 Decreased viability GR00221-A-2 9.58 AKT1 KRAS
5 Decreased viability GR00221-A-3 9.58 AKT1 CDKN2A
6 Decreased viability GR00221-A-4 9.58 AKT1 CDKN2A EGFR
7 Decreased viability GR00301-A 9.58 CDH1 KRAS
8 Decreased viability GR00381-A-1 9.58 KRAS
9 Decreased cell migration GR00055-A-1 9.35 AKT1 EGFR KRAS MUC1 TIMP2

MGI Mouse Phenotypes related to Gallbladder Cancer:

43 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.42 EGFR FHIT KRAS ERBB2 ABCB4 CDH1
2 endocrine/exocrine gland MP:0005379 10.41 EGFR KRAS ERBB2 ABCB4 CDH1 AFP
3 cardiovascular system MP:0005385 10.35 ERBB2 EGFR CDKN2A ABCB4 CDH1 AKT1
4 cellular MP:0005384 10.35 CDKN2A ERBB2 EGFR AKT1 ABCB4 CDH1
5 hematopoietic system MP:0005397 10.32 EGFR FHIT CDKN2A AKT1 ABCB4 NMT1
6 immune system MP:0005387 10.32 EGFR FHIT KRAS CDKN2A ABCB4 CDH1
7 mortality/aging MP:0010768 10.31 ERBB2 EGFR FHIT KRAS CDH1 AFP
8 digestive/alimentary MP:0005381 10.3 EGFR FHIT KRAS ERBB2 ABCB4 CDH1
9 growth/size/body region MP:0005378 10.3 CDKN2A ERBB2 EGFR AKT1 ABCB4 CDH1
10 embryo MP:0005380 10.2 CDKN2A ERBB2 EGFR AKT1 CDH1 KRAS
11 neoplasm MP:0002006 10.2 EGFR FHIT KRAS ERBB2 ABCB4 CDH1
12 integument MP:0010771 10.16 ERBB2 EGFR FHIT CDKN2A AKT1 CDH1
13 liver/biliary system MP:0005370 10.03 CDKN2A EGFR AKT1 ABCB4 AFP KRAS
14 muscle MP:0005369 9.97 CDKN2A ERBB2 EGFR AKT1 MMP2 KRAS
15 reproductive system MP:0005389 9.93 ERBB2 EGFR KRAS ABCB4 CDH1 AFP
16 normal MP:0002873 9.91 ERBB2 EGFR AKT1 CDH1 MMP2 KRAS
17 respiratory system MP:0005388 9.65 ERBB2 EGFR CDKN2A AKT1 MLH1 KRAS
18 skeleton MP:0005390 9.28 CDKN2A ERBB2 EGFR AKT1 ABCB4 MMP2

Drugs & Therapeutics for Gallbladder Cancer

Drugs for Gallbladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1
3 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
6
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
7
Epirubicin Approved Phase 3,Phase 1 56420-45-2 41867
8
Somatostatin Approved, Investigational Phase 3 38916-34-6, 51110-01-1 53481605
9
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
10
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
15
Morphine Approved, Investigational Phase 3 57-27-2 5288826
16
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
17
Citalopram Approved Phase 3 59729-33-8 2771
18
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 143 6006
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
20 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
23 Antimetabolites Phase 3,Phase 2,Phase 1
24 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
25 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 3,Phase 2,Phase 1
28 Antiviral Agents Phase 3,Phase 2,Phase 1
29 Analgesics Phase 3,Phase 1
30 Peripheral Nervous System Agents Phase 3,Phase 1
31 Hormone Antagonists Phase 3
32 Hormones Phase 3
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
34 Dermatologic Agents Phase 3,Phase 2,Phase 1
35 Dihematoporphyrin Ether Phase 3,Phase 2
36 Ether Phase 3,Phase 2
37 Photosensitizing Agents Phase 3,Phase 2,Phase 1
38 Adjuvants, Anesthesia Phase 3
39 Analgesics, Opioid Phase 3
40 Anesthetics Phase 3
41 Anesthetics, General Phase 3
42 Anesthetics, Intravenous Phase 3
43 Central Nervous System Depressants Phase 3
44 Narcotics Phase 3
45 Anti-Anxiety Agents Phase 3
46 Antiemetics Phase 3
47 Anti-Inflammatory Agents Phase 3
48 Antineoplastic Agents, Hormonal Phase 3
49 Antipruritics Phase 3
50 Antipsychotic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 165)

# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
3 Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block. Completed NCT00391183 Phase 2, Phase 3
4 New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma Completed NCT01053390 Phase 3 Somatostatin;epirubicin, cisplatin, LV(Leucovorin)、 5-FU(5-Fluorouracil)
5 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
6 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
7 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
8 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
9 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
12 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
13 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
14 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
15 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Recruiting NCT02798510 Phase 3 capecitabine;gemcitabine
16 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
17 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Not yet recruiting NCT02867865 Phase 2, Phase 3 Gemcitabine;Cisplatin
18 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
19 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
20 XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Terminated NCT00090025 Phase 3 becatecarin;5-Fluorouracil Plus Leucovorin
21 Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo Terminated NCT00332280 Phase 2, Phase 3 AMT2003
22 Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery Withdrawn NCT00253617 Phase 3 porfimer sodium
23 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Unknown status NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
24 A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
25 Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
26 HAI Via Interventionally Implanted Port Catheter Systems Unknown status NCT00356161 Phase 2
27 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer Completed NCT01308840 Phase 2 Panitumumab;oxaliplatin;gemcitabine
28 Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer Completed NCT00660140 Phase 2 Gemcitabine;Carboplatin
29 Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer Completed NCT00123825 Phase 2 Gemcitabine;Cisplatin
30 Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
31 Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
32 S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
33 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
34 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
35 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
36 Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Completed NCT00003557 Phase 2 dolastatin 10
37 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2 Bevacizumab;Gemcitabine;Oxaliplatin
38 Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer Completed NCT00075504 Phase 2 triapine;gemcitabine
39 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
40 Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer Completed NCT00003276 Phase 2 irinotecan hydrochloride
41 Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Completed NCT00033462 Phase 2 erlotinib hydrochloride
42 Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride
43 DX-8951f in Treating Patients With Biliary Cancer Completed NCT00005938 Phase 2 exatecan mesylate
44 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma Completed NCT00338988 Phase 2 Capecitabine;Oxaliplatin
45 Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy Completed NCT00919061 Phase 2 Gemcitabine;Cisplatin;Sorafenib
46 Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct Completed NCT01153750 Phase 2 Glivec
47 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
48 A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts Completed NCT01007552 Phase 2 Gemcitabine, Capecitabine and Bevacizumab
49 Avastin and Tarceva for Upper Gastrointestinal Cancers Completed NCT00350753 Phase 2 Erlotinib and bevacizumab
50 Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study Completed NCT00747097 Phase 2 gemcitabine + cetuximab

Search NIH Clinical Center for Gallbladder Cancer

Cochrane evidence based reviews: gallbladder neoplasms

Genetic Tests for Gallbladder Cancer

Anatomical Context for Gallbladder Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Gallbladder Cancer:

18
The Gallbladder

MalaCards organs/tissues related to Gallbladder Cancer:

38
Liver, Lymph Node, Lung, Eye, Skin, Small Intestine, Testes

Publications for Gallbladder Cancer

Articles related to Gallbladder Cancer:

(show top 50) (show all 757)
# Title Authors Year
1
Association of TERT-CLPTM1L and 8q24 Common Genetic Variants with Gallbladder Cancer Susceptibility and Prognosis in North Indian Population. ( 29450669 )
2018
2
PLZF inhibits proliferation and metastasis of gallbladder cancer by regulating IFIT2. ( 29358655 )
2018
3
Survey Results of the Expert Meeting on Laparoscopic Surgery for Gallbladder Cancer and a Review of Relevant Literature. ( 29339658 )
2018
4
miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M. ( 29435072 )
2018
5
Chemoradiotherapy Versus Chemotherapy Alone for Unresected Nonmetastatic Gallbladder Cancer: National Practice Patterns and Outcomes. ( 29295882 )
2018
6
Gallbladder Cancer: Complete Resection after Second Line Treatment in Stage IV Disease. ( 29292472 )
2018
7
Laparoscopic Surgery for Gallbladder Cancer: An Expert Consensus Statement. ( 29339660 )
2018
8
Trends in Gallbladder Cancer Incidence and Survival in Korea. ( 29370591 )
2018
9
Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway. ( 28766687 )
2017
10
Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. ( 28738935 )
2017
11
Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks. ( 29188076 )
2017
12
Indication of extrahepatic bile duct resection for gallbladder cancer. ( 28875312 )
2017
13
The risk of incidental gallbladder cancer is negligible in macroscopically normal cholecystectomy specimens. ( 29248400 )
2017
14
MiR-143-5p Deficiency Triggers EMT and Metastasis by Targeting HIF-1I+ in Gallbladder Cancer. ( 28803245 )
2017
15
Lymph node micrometastasis in gallbladder cancer. ( 28782079 )
2017
16
Perineural infiltration as a prognostic factor in surgically treated gallbladder cancer A single center experience and literature review. ( 29339591 )
2017
17
Laparoscopic extended cholecystectomy for T3 gallbladder cancer. ( 29218663 )
2017
18
INCIDENTAL GALLBLADDER CANCER - THE FIRST REPORT FROM SUB-SAHARAN AFRICA. ( 28876646 )
2017
19
Healthy dietary patterns and incidence of biliary tract and gallbladder cancer in a prospective study of women and men. ( 27870981 )
2017
20
The technique of laparoscopic hepatic bisegmentectomy with regional lymphadenectomy for gallbladder cancer. ( 28928327 )
2017
21
Comparative Analysis of Mutational Profile of Sonic hedgehog Gene in Gallbladder Cancer. ( 28058596 )
2017
22
Laparoscopic versus open treatment of gallbladder cancer: A systematic review and meta-analysis. ( 28782743 )
2017
23
Patterns of initial failure after resection for gallbladder cancer: implications for adjuvant radiotherapy. ( 29249117 )
2017
24
Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients. ( 28900470 )
2017
25
Prognostic significance of pre-operative inflammatory markers in resected gallbladder cancer: a systematic review. ( 29205753 )
2017
26
Threonine and tyrosine kinase may serve as a prognostic biomarker for gallbladder cancer. ( 28883705 )
2017
27
DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer. ( 28129656 )
2017
28
Decreased expression of hsaa89miRa89372 predicts poor prognosis in patients with gallbladder cancer by affecting chloride intracellular channel 1. ( 28944858 )
2017
29
Retracted: Long Noncoding RNA KIAA0125 Potentiates Cell Migration and Invasion in Gallbladder Cancer. ( 28929110 )
2017
30
Biofilm Producing Salmonella Typhi: Chronic Colonization and Development of Gallbladder Cancer. ( 28858232 )
2017
31
Isolation and identification of tumor-initiating cell properties in human gallbladder cancer cell lines using the marker cluster of differentiation 133. ( 29344142 )
2017
32
WNT inhibitory factor 1 promoter hypermethylation is an early event during gallbladder cancer tumorigenesis that predicts poor survival. ( 28438695 )
2017
33
The NmrA-like family domain containing 1 pseudogene Loc344887 is amplified in gallbladder cancer and promotes epithelial-mesenchymal transition. ( 28245089 )
2017
34
MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer. ( 28427077 )
2017
35
cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF-I_B pathway. ( 28295868 )
2017
36
Predicting Resectability in Gallbladder Cancer: the Tata Memorial Hospital Staging System. ( 28812197 )
2017
37
Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease. ( 29161283 )
2017
38
Epigenetic Downregulation of PTEN in Gallbladder Cancer. ( 28124240 )
2017
39
Extended Lymphadenectomy Is Required for Incidental Gallbladder Cancer Independent of Cystic Duct Lymph Node Status. ( 28752405 )
2017
40
SNORA74B gene silencing inhibits gallbladder cancer cells by inducing PHLPP and suppressing Akt/mTOR signaling. ( 28212545 )
2017
41
Sister Mary Joseph's nodule: Two rare cases of inoperable gallbladder cancer. ( 29199657 )
2017
42
Long non-coding RNA LINC00152 promotes gallbladder cancer metastasis and epithelial-mesenchymal transition by regulating HIF-1I+ via miR-138. ( 28077595 )
2017
43
Arctigenin induced gallbladder cancer senescence through modulating epidermal growth factor receptor pathway. ( 28459363 )
2017
44
Common genetic variation and risk of gallbladder cancer in India: a case-control genome-wide association study. ( 28274756 )
2017
45
Casticin induces apoptosis and G0/G1 cell cycle arrest in gallbladder cancer cells. ( 28070171 )
2017
46
Mortality trend of gallbladder cancer in AraucanA-a Region, Chile, 2004-2014. ( 28885998 )
2017
47
Incidental gallbladder cancer at cholecystectomy. ( 29197189 )
2017
48
The clinical significance and underlying correlation of pStat-3 and integrin I+vI^6 expression in gallbladder cancer. ( 28061445 )
2017
49
Re: Incidental Gallbladder Cancer Visualized From Posttreatment 131I Whole-Body Scan. ( 28079570 )
2017
50
A modified surgical approach of hepatopancreatoduodenectomy for advanced gallbladder cancer: Report of two cases and literature review. ( 29270743 )
2017

Variations for Gallbladder Cancer

ClinVar genetic disease variations for Gallbladder Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
2 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
3 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
4 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
5 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
6 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
7 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
8 ERBB2 NM_004448.3(ERBB2): c.2524G> A (p.Val842Ile) single nucleotide variant Pathogenic/Likely pathogenic rs1057519738 GRCh37 Chromosome 17, 37881332: 37881332
9 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407

Expression for Gallbladder Cancer

Search GEO for disease gene expression data for Gallbladder Cancer.

Pathways for Gallbladder Cancer

Pathways related to Gallbladder Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 AKT1 CDH1 CDKN2A EGFR ERBB2 KRAS
2
Show member pathways
13.38 AKT1 EGFR ERBB2 KRAS MMP2 MUC1
3
Show member pathways
13.03 AKT1 CDH1 CDKN2A EGFR ERBB2 FHIT
4
Show member pathways
12.74 AKT1 EGFR ERBB2 KRAS TP53
5
Show member pathways
12.72 AKT1 CDH1 ERBB2 KRAS PTGS2 TP53
6
Show member pathways
12.61 AKT1 EGFR ERBB2 KRAS MMP2 TP53
7
Show member pathways
12.58 AKT1 CDKN2A EGFR ERBB2 KRAS MMP2
8
Show member pathways
12.58 AKT1 CDH1 CDKN2A EGFR ERBB2 KRAS
9 12.58 AKT1 CDH1 CDKN2A EGFR ERBB2 KRAS
10 12.54 CDKN2A EGFR ERBB2 KRAS PTGS2 TP53
11
Show member pathways
12.51 AKT1 EGFR ERBB2 KRAS TP53
12
Show member pathways
12.49 AKT1 EGFR ERBB2 KRAS TP53
13
Show member pathways
12.45 AKT1 EGFR ERBB2 KRAS TP53
14
Show member pathways
12.4 AKT1 CDH1 EGFR ERBB2 KRAS MUC1
15
Show member pathways
12.34 AKT1 EGFR ERBB2 PTGS2
16
Show member pathways
12.33 AKT1 EGFR ERBB2 KRAS
17 12.32 AKT1 EGFR ERBB2 KRAS MMP2 TP53
18
Show member pathways
12.24 AKT1 EGFR ERBB2 KRAS TP53
19 12.21 AKT1 EGFR ERBB2 KRAS
20 12.19 AKT1 CDKN2A KRAS TP53
21 12.18 AKT1 CDH1 EGFR KRAS TP53
22
Show member pathways
12.16 AKT1 EGFR ERBB2 KRAS
23
Show member pathways
12.14 AKT1 EGFR ERBB2 MMP2
24
Show member pathways
12.12 AKT1 CDKN2A EGFR ERBB2 KRAS TP53
25 12.09 AFP EGFR MLH1 MMP2 TP53
26
Show member pathways
12.08 AKT1 EGFR ERBB2 KRAS
27 12.08 AKT1 EGFR KRAS TP53
28
Show member pathways
12.07 AKT1 EGFR KRAS TP53
29
Show member pathways
12.04 AKT1 EGFR ERBB2 TP53
30 12.03 AKT1 CDKN2A ERBB2 KRAS TP53
31 12.02 CDH1 CEACAM5 MMP2 MUC1
32 12.01 AKT1 MMP2 MUC1 PTGS2 TP53
33 12 AKT1 CDKN2A KRAS MGMT MLH1 TP53
34 11.89 AKT1 FHIT PTGS2 TP53
35 11.84 AKT1 CDKN2A EGFR KRAS MGMT TP53
36 11.81 AFP AKT1 TP53
37 11.78 AKT1 CDH1 EGFR KRAS MLH1 MMP2
38
Show member pathways
11.76 AKT1 CDKN2A TP53
39 11.75 CDH1 EGFR ERBB2
40 11.74 AKT1 CDKN2A ERBB2 MLH1 TP53
41 11.72 AKT1 EGFR ERBB2
42 11.7 AKT1 EGFR MMP2
43 11.7 AKT1 ERBB2 TP53
44 11.69 AKT1 EGFR MMP2
45 11.66 EGFR MMP2 TIMP2
46 11.64 AKT1 EGFR ERBB2 KRAS TP53
47 11.62 EGFR ERBB2 KRAS
48
Show member pathways
11.62 AKT1 EGFR ERBB2 MMP2
49 11.59 CDKN2A EGFR MMP2 TP53
50 11.58 AKT1 PTGS2 TP53

GO Terms for Gallbladder Cancer

Biological processes related to Gallbladder Cancer according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.91 AKT1 CEACAM5 EGFR MGMT PTGS2 TP53
2 aging GO:0007568 9.85 AKT1 PTGS2 TIMP2 TP53
3 positive regulation of protein phosphorylation GO:0001934 9.84 AKT1 EGFR ERBB2 KRAS
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 AKT1 EGFR PTGS2
5 positive regulation of cell growth GO:0030307 9.8 AKT1 EGFR ERBB2
6 extracellular matrix disassembly GO:0022617 9.8 CDH1 MMP2 TIMP2
7 cellular response to mechanical stimulus GO:0071260 9.79 AKT1 EGFR PTGS2
8 cellular response to organic cyclic compound GO:0071407 9.79 ABCB4 AKT1 MGMT
9 Ras protein signal transduction GO:0007265 9.78 CDKN2A KRAS TP53
10 positive regulation of MAP kinase activity GO:0043406 9.77 EGFR ERBB2 KRAS
11 response to cytokine GO:0034097 9.77 PTGS2 TIMP2 TP53
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 AKT1 EGFR PTGS2
13 response to oxidative stress GO:0006979 9.76 AKT1 EGFR PTGS2 TP53
14 epidermal growth factor receptor signaling pathway GO:0007173 9.75 AKT1 EGFR KRAS
15 cellular response to growth factor stimulus GO:0071363 9.73 AKT1 EGFR ERBB2
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.69 AKT1 EGFR PTGS2
17 cellular response to epidermal growth factor stimulus GO:0071364 9.67 AKT1 EGFR ERBB2
18 ERBB2 signaling pathway GO:0038128 9.65 EGFR ERBB2 KRAS
19 cellular response to reactive oxygen species GO:0034614 9.58 AKT1 EGFR TP53
20 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.57 AKT1 EGFR
21 negative regulation of immature T cell proliferation in thymus GO:0033088 9.52 CDKN2A ERBB2
22 response to organic substance GO:0010033 9.46 ABCB4 AKT1 CDH1 PTGS2
23 positive regulation of vasoconstriction GO:0045907 9.43 AKT1 EGFR PTGS2
24 response to drug GO:0042493 9.43 ABCB4 CDH1 MGMT PTGS2 TIMP2 TP53
25 maintenance of permeability of blood-brain barrier GO:0035633 9.37 ABCB4 PTGS2
26 response to UV-A GO:0070141 9.32 AKT1 EGFR
27 response to organic cyclic compound GO:0014070 9.02 ABCB4 EGFR MGMT PTGS2 TP53

Molecular functions related to Gallbladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.55 AKT1 EGFR ERBB2 FHIT KRAS
2 protein phosphatase binding GO:0019903 9.5 EGFR ERBB2 TP53
3 identical protein binding GO:0042802 9.5 AKT1 CDH1 CEACAM5 EGFR ERBB2 FHIT
4 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.26 EGFR ERBB2
5 nitric-oxide synthase regulator activity GO:0030235 8.62 AKT1 EGFR

Sources for Gallbladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....